Filgrastim support in allogeneic HSCT for myeloid malignancies: A review of the role of G-CSF and the implications for current practice

Bone Marrow Transplantation

Volumn 43, Issue 5, 2009, Pages 351-356

  Battiwalla, M ^a   McCarthy, P L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ANGINA PECTORIS; APLASTIC ANEMIA; BONE MARROW CELL; BONE PAIN; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CELL STIMULATION; CHROMOSOME 7; CHROMOSOME ABERRATION; CHRONIC DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE COURSE; DISEASE DURATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GOUT; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; KERATITIS; LEUKEMOGENESIS; MOLECULAR EVOLUTION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; SPLEEN RUPTURE; STEM CELL MOBILIZATION; STROKE; VASCULITIS;

ANEMIA, APLASTIC; CHROMOSOMES, HUMAN, PAIR 7; FILGRASTIM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MONOSOMY; NEUTROPENIA; TRANSPLANTATION, HOMOLOGOUS;

EID: 62549158193     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.443     Document Type: Review

References (57)

1. Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R et al Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985; 82: 1526-1530.
2. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C et al Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737-1746.
3. Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 1996; 5: 491-501.
4. Filgrastim (Neuogen) Package Insert Amgen, Thousand Oaks, CA.
5. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1996; 14 1957-1960.
6. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496-2502.
7. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710-4718.
8. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: Final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27-34.
9. Dombret H. Granulocytic colony-stimulating factors in the management of patients with acute myeloid leukemia. Hematol Cell Ther 1996; 38: 231-240.
10. Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Mrozek K, Swann VL et al. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood 1996; 87: 1484-1494.
11. Sultana TA, Harada H, Ito K, Tanaka H, Kyo T, Kimura A. Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia. Br J Haematol 2003; 121: 63-75.
12. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803-811.
13. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
14. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
15. Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S et al Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009-1013.
16. Bessho M, Hotta T, Ohyashiki K, Takahashi T, Mizoguchi H, Asano S et al. Multicenter prospective study of clonal complications in adult aplastic anemia patients following recombinant human granulocyte colony-stimulating factor (lenograstim) administration. Int J Hematol 2003; 77: 152-158.
17. Konoplev S, Medeiros LJ, Lennon PA, Prajapati S, Kanungo A, Lin P. Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia. Cancer 2007; 110: 1520-1526.
18. Liu CZ, Persad R, Inghirami G, Sen F, Amorosi E, Goldenberg A et al Transient atypical monocytosis mimic acute myelomonocytic leukemia in post-chemotherapy patients receiving G-CSF: Report of two cases. Clin Lab Haematol 2004; 26: 359-362.
19. Nishimura M, Yamada T, Andoh T, Tao T, Emoto M, Ohji T et al. Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/CsA/ G-CSF combined therapy. Int J Hematol 1998; 68: 203-211.
20. Yamazaki E, Kanamori H, Taguchi J, Harano H, Mohri H, Okubo T. The evidence of clonal evolution with monosomy 7 in aplastic anemia following granulocyte colony-stimulating factor using the polymerase chain reaction. Blood Cells Mol Dis 1997; 23: 213-218.
21. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002; 100: 786-790.
22. Kaito K, Kobayashi M, Katayama T, Masuoka H, Shimada T, Nishiwaki K et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 1998; 103: 297-303.
23. Imashuku S, Hibi S, Bessho F, Tsuchida M, Nakahata T, Miyazaki S et al. Detection of myelodysplastic syndrome/acute myeloid leukemia evolving from aplastic anemia in children, treated with recombinant human G-CSF. Haematologica 2003; 88: ECR31.
24. Socie G, Mary JY, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109: 2794-2796.
25. White SM, Alarcon MH, Tweardy DJ. Inhibition of granulocyte colony-stimulating factor-mediated myeloid maturation by low level expression of the differentiation-defective class IV granulocyte colony-stimulating factor receptor isoform. Blood 2000; 95: 3335-3340.
26. White SM, Ball ED, Ehmann WC, Rao AS, Tweardy DJ. Increased expression of the differentiation-defective granulocyte colony-stimulating factor receptor mRNA isoform in acute myelogenous leukemia. Leukemia 1998; 12: 899-906.
27. Sloand EM, Yong AS, Ramkissoon S, Solomou E, Bruno TC, Kim S et al Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci USA 2006; 103: 14483-14488.
28. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: The MD Anderson Cancer Center experience. Transfusion 1999; 39: 555-560.
29. Anderlini P, Przepiorka D, Korbling M, Champlin R. Blood stem cell procurement: Donor safety issues. Bone Marrow Transplant 1998; 21(Suppl 3): S35-S39.
30. Anderlini P, Przepiorka D, Lauppe J, Seong D, Giralt S, Champlin R et al. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 1997; 97: 485-487.
31. Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: Considerations for donors. Blood 1997; 90: 903-908.
32. Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: A novel mediator of T cell tolerance. J Immunol 2005; 175: 7085-7091.
33. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709.
34. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007; 13: 1461-1468.
35. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term followup of a randomized trial. Blood 2002; 100: 415-419.
36. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L et al Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: Long-term results of a randomized study. Blood 2002; 100: 3128-3134.
37. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269-2274.
38. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S et al Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001; 97: 2514-2521.
39. Rondelli D, Raspadori D, Anasetti C, Bandini G, Re F, Arpinati M et al. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 1998; 22: 631-637.
40. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17: 101-109.
41. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416-423.
42. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza Jr FR, Ringden O et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-4880.
43. Khoury HJ, Loberiza Jr FR, Ringden O, Barrett AJ, Bolwell BJ, Cahn JY et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107: 1712-1716.
44. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207-5215.
45. Ho VT, Mirza NQ, Junco Dd D, Okamura T, Przepiorka D. The effect of hematopoietic growth factors on the risk of graft-vs- host disease after allogeneic hematopoietic stem cell transplantation: A meta-analysis. Bone Marrow Transplant 2003; 32: 771-775.
46. Rocha V, Wagner Jr JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342: 1846-1854.
47. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815-1822.
48. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611-1618.
49. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
50. Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J et al. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: Effect on costs from a hospital perspective. Pharmacoeconomics 2007; 25: 343-351.
51. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. J Natl Compr Canc Netw 2005; 3: 557-571.
52. Fenaux P, Preudhomme C, Lai JL, Morel P, Beuscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: A report on 283 cases. Br J Haematol 1989; 73: 61-67.
53. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263-270.
54. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490.
55. Rutella S, Rumi C, Sica S, Leone G. Recombinant human granulocyte colony-stimulating factor (rHuG-CSF): Effects on lymphocyte phenotype and function. J Interferon Cytokine Res 1999; 19: 989-994.
56. Rutella S, Rumi C, Sica S, Leone G. Induction of T-cell mitogenic unresponsiveness by recombinant human granulocyte colony-stimulating factor (rHuG-CSF). Br J Cancer 2000; 82: 1610; author reply 1611.
57. Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transplantation. Blood 1997; 90: 453-463.